Departments of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Psychiatry, Stony Brook University School of Medicine, Stony Brook, NY, USA.
Neuropsychopharmacology. 2018 Mar;43(4):751-760. doi: 10.1038/npp.2017.138. Epub 2017 Jun 30.
Individuals with drug use disorders seek drugs over other rewarding activities, and exhibit neurochemical deficits related to dopamine, which is involved in value-based learning and decision-making. Thus, a dopaminergic disturbance may underpin drug-biased choice in addiction. Classical drug-choice assessments, which offer drug-consumption opportunities, are inappropriate for addicted individuals seeking treatment or abstaining. Fifteen recently abstinent methamphetamine users and 15 healthy controls completed two laboratory paradigms of 'simulated' drug choice (choice for drug-related vs affectively pleasant, unpleasant, and neutral images), and underwent positron emission tomography measurements of dopamine D2-type receptor availability, indicated by binding potential (BP) for [F]fallypride. Thirteen of the methamphetamine users and 10 controls also underwent [C]NNC112 PET scans to measure dopamine D1-type receptor availability. Group analyses showed that, compared with controls, methamphetamine users chose to view more methamphetamine-related images on one task, with a similar trend on the second task. Regression analyses showed that, on both tasks, the more methamphetamine users chose to view methamphetamine images, specifically vs pleasant images (the most frequently chosen images across all participants), the lower was their D2-type BP in the lateral orbitofrontal cortex, an important region in value-based choice. No associations were observed with D2-type BP in striatal regions, or with D1-type BP in any region. These results identify a neurochemical correlate for a laboratory drug-seeking paradigm that can be administered to treatment-seeking and abstaining drug-addicted individuals. More broadly, these results refine the central hypothesis that dopamine-system deficits contribute to drug-biased decision-making in addiction, here showing a role for the orbitofrontal cortex.
个体患有药物使用障碍,会将药物置于其他奖励活动之上,表现出与多巴胺相关的神经化学缺陷,而多巴胺参与基于价值的学习和决策。因此,多巴胺能紊乱可能是成瘾者药物偏好选择的基础。经典的药物选择评估提供了药物消费的机会,但对于寻求治疗或戒断的成瘾者来说并不合适。15 名最近戒断的甲基苯丙胺使用者和 15 名健康对照者完成了两种“模拟”药物选择的实验室范式(对与药物相关的图像与情感愉悦、不愉快和中性图像的选择),并进行了正电子发射断层扫描测量多巴胺 D2 型受体可用性,以 [F]fallypride 的结合潜能 (BP) 表示。13 名甲基苯丙胺使用者和 10 名对照者还接受了 [C]NNC112 PET 扫描,以测量多巴胺 D1 型受体可用性。组分析表明,与对照组相比,甲基苯丙胺使用者在一项任务中选择观看更多与甲基苯丙胺相关的图像,在第二项任务中也出现类似趋势。回归分析表明,在两项任务中,甲基苯丙胺使用者选择观看更多甲基苯丙胺图像的次数越多,特别是与愉悦图像相比(所有参与者中选择最多的图像),他们的外侧眶额皮质中的 D2 型 BP 越低,这是一个基于价值的选择的重要区域。在纹状体区域没有观察到与 D2 型 BP 的关联,也没有在任何区域观察到与 D1 型 BP 的关联。这些结果确定了一种可以在治疗中使用的实验室觅药范式的神经化学相关性,并正在寻求和戒断药物成瘾者。更广泛地说,这些结果完善了多巴胺系统缺陷导致成瘾者药物偏好决策的核心假设,这里显示了眶额叶皮层的作用。